Gala vs Hers: Which GLP-1 Provider Is Better?
By Iacob Pastina, Independent Researcher
Hers beats Gala overall, scoring 7.3/10 vs 7/10. Gala is more affordable at $149/mo vs $199/mo. Choose Gala for users who want low-cost compounded tirzepatide and a built-i. Choose Hers for women who want brand-name wegovy (injection or pill) at $149.
A side-by-side comparison of Gala and Hers covering pricing, scores, medication types, insurance, and more to help you decide.
Gala
#40 of 42Telehealth platform offering compounded semaglutide and tirzepatide at competitive pricing, plus a paid path to brand semaglutide. Differentiator: a dedicated iOS GLP-1 tracker app for users who want to log dosing, weight, and side effects in one place.
Visit GalaHers
#31 of 42The women's health arm of Hims & Hers Health (NYSE: HIMS). In 2026 Hers signed a direct Novo Nordisk partnership adding FDA-approved Wegovy (pen and pill) at $149/mo and Zepbound via the Lilly partnership — alongside their existing compounded semaglutide and new compounded tirzepatide programs.
Visit Hers| Feature | Gala | Hers |
|---|---|---|
| Our Score | 7/10 | 7.3/10 |
| Starting Price | $149/mo | $199/mo |
| Medication Type | Both | Both |
| Insurance Accepted | No | No |
| Best For | Users who want low-cost compounded tirzepatide and a built-in iOS tracker app for daily progress logging | Women who want brand-name Wegovy (injection or pill) at $149/mo via the 2026 Novo Nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand |
| Ranking | #40 | #31 |
Pros & Cons Compared
Gala
Pros
- +Compounded tirzepatide as low as $149/mo on the longest commitment plan — among the cheapest tirz options on the market
- +$199/mo entry pricing on a 3-month plan for compounded semaglutide — competitive in the mid-tier
- +Dedicated 'Gala GLP-1 Tracker' iOS app for dosing, weight, and side-effect logging — uncommon among compounded-only platforms
- +Both semaglutide and tirzepatide available, plus a brand-name semaglutide path for users who specifically want FDA-approved
Cons
- −Brand-name semaglutide pricing ($1,299/mo) is significantly above market — NovoCare direct pricing for Wegovy is $349/mo
- −Mixed Trustpilot reviews mention dosing inconsistencies and slow customer service responsiveness
- −Newer brand (Delaware-registered, limited public company history) — less track record than established platforms like Henry Meds or Sprout
- −No published lab panels or specialty clinical oversight — state-licensed prescriber review is the standard, not differentiated
Hers
Pros
- +2026 Novo Nordisk partnership — FDA-approved Wegovy pen and Wegovy oral pill from $149/mo, one of the lowest brand-name GLP-1 prices on the market
- +Zepbound access via the Lilly/Hims-Hers partnership announced 2026
- +Publicly traded company (NYSE: HIMS) with strong financial backing and regulatory compliance
- +Broader women's health platform — integrates weight loss with hormonal, skin, and wellness services
Cons
- −Membership + medication are billed separately ($39 first month / $149 ongoing membership) — watch the all-in math
- −Generic support experience — large patient volume means less personalized attention
- −Compounded pricing starts at $199/mo but stepped pricing applies at higher doses
- −Zepbound access priced at ~$1,899/mo (brand cash) via the Lilly partnership — read as access, not value
Our Verdict
Hers edges out Gala with a score of 7.3/10 vs 7/10. If budget is your priority, Gala starts at $149/mo compared to Hers's $199/mo. Choose Gala if you want: users who want low-cost compounded tirzepatide and a built-in ios tracker app for daily progress logging. Choose Hers if you want: women who want brand-name wegovy (injection or pill) at $149/mo via the 2026 novo nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand.